Non–Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement


Mark G. Kris, MD, on NSCLC: Juggling Sequence and Agent Choices in Lung Cancer

Posted: Monday, June 4, 2018

Mark G. Kris, MD, of Memorial Sloan Kettering Cancer Center, discusses three key studies on adjuvant vs neoadjuvant chemotherapy, radiotherapy plus chemotherapy, and nivolumab added to radiotherapy—how and when to administer in non–small cell lung cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.